503 Pneumonitis with anti-PD-1/PD-L1 therapy

Anti-PD1-Induced Pneumonitis: Capturing the Hidden Enemy

Anti-PD1 antibodies have led to a therapeutic shift in cancer treatment. Although classically described as "well tolerated," these drugs can lead to severe immune-related adverse events. Using CT scan imaging, Nishino and colleagues describe different radiologic patterns and their possible relation to severity of several cases of anti-PD1-induced pneumonitis. Clin Cancer Res; 22(24); 5956-8. ©2016 AACRSee related article by Nishino et al., p. 6051.

Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer

Monoclonal antibodies targeting programmed cell death protein-1 (PD-1) represent a new treatment paradigm in non-small cell lung cancer. Three phase III trials have demonstrated a survival benefit and improved tolerability of nivolumab and pembrolizumab when compared with standard second-line chemotherapy. Nevertheless, the adverse events associated with PD-1 inhibitors are unique; early recognition and treatment are essential. This review summarizes the required monitoring and appropriate management of immune-related adverse events in lung cancer patients receiving these agents.

THE ONCOLOGIST

2017;22:70-80 IMPLICATIONS FOR PRACTICE: : The potential adverse events of immune checkpoint inhibitors differ from conventional chemotherapy and can require a multidisciplinary approach. Continued education is important for all physicians to ensure optimal care for patients.